Market Performance of Vitrafy Life Sciences (VFY.AX)
| Item | Value |
|---|---|
| Last close | AUD 2.75 |
| Daily change | –5.24 % (down) |
| Trading volume (last 24 h) | AUD 195,300 |
| Shares outstanding | 80.4 million |
| Market capitalisation | AUD 217.9 million |
| 20‑day simple moving average | AUD 2.64 |
| 52‑week high | AUD 4.66 (17 Aug 2026) |
| 52‑week low | AUD 1.20 (22 Oct 2025) |
| Year‑end change (last month) | –18.62 % |
Vitrafy Life Sciences’ shares ended the trading session on 20 October 2026 at AUD 2.75, a decline of 5.24 % from the previous close. The price movement coincided with a daily trading volume of AUD 195.3 k. The company’s market capitalisation stands at AUD 217.9 million, based on 80.4 million shares outstanding.
The stock’s performance relative to its 200‑day simple moving average (AUD 2.64) indicates a short‑term bearish trend, while its 52‑week high of AUD 4.66 and low of AUD 1.20 demonstrate significant volatility over the past year.
Corporate Actions
Appointment of Chief Financial Officer
- New CFO: Jan Gielen
- Start date: 1 February 2027
- Background: Over 20 years of finance experience in listed and private technology and medical‑device companies, most recently CFO of PolyNovo Limited during a period of growth and international expansion.
- Former CFO: Simon Martin will remain in an advisory capacity for six months, with the possibility of extension.
Equity Incentive Plan Shares
- Number of shares: 5,848 ordinary shares issued under the equity incentive plan.
- Issue date: 19 October 2026.
- Consideration: Nil.
- Listing: Shares are to be quoted in the existing VFY class and will rank equally with previously issued shares from the issue date.
- Application: Submitted to the ASX; details referenced in the company’s 2025 AGM notice.
Related Stock Performance (Last 24 h)
| Ticker | Price (AUD) | Change | Market Cap (AUD mn) | P/E Ratio |
|---|---|---|---|---|
| LGI.AX | 2.50 | +0.8 % | 260.7 | – |
| SVL.AX | 0.12 | 0 % | 255.2 | – |
| MMI.AX | 0.82 | +0.61 % | 256.3 | 136.07 |
| RHI.AX | 4.05 | +1.79 % | 251.1 | 12.73 |
| KAN.AX | 1.06 | –1.37 % | 254.8 | 12.53 |
The table summarizes the performance of five related Australian stocks over the past 24 hours, including their current price, daily change, market capitalisation, and, where applicable, price‑to‑earnings ratios.
Summary
Vitrafy Life Sciences experienced a 5.24 % decline in share price during the 20 October 2026 trading session, with a market capitalisation of AUD 217.9 million and a daily volume of AUD 195.3 k. The company has announced the appointment of Jan Gielen as its new chief financial officer, effective 1 February 2027, and has applied to the ASX for the quotation of 5,848 incentive‑plan shares issued at nil consideration. The related Australian stocks listed in the table show varied performance, with LGI.AX and RHI.AX posting modest gains and KAN.AX experiencing a decline.
